JPRN-UMIN000022257已完成未知
Prediction of the lenalidomide toxicity and its therapeutic efficacy in multiple myeloma patients by measuring its plasma concentration - Prediction of the lenalidomide toxicity by measuring its plasma concentration
Japan Community Health care Organization Kyoto Kuramaguchi Medical Center0 个研究点目标入组 30 人开始时间: 2016年5月16日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Multiple myeloma patient who recieved anti-cancer drugs in additon to lenalidomide
研究者
相似试验
已完成
1 期
Evaluation of the Feasible dose of Lenalidomide as maintenance therapy after Allogeneic hematopoietic stem cell Transplantation for multiple myelomamultiple myeloma (including plasma cell leukemia)JPRN-UMIN000010470Division of Hematology, Saitama Medical Center, Jichi Medical University9
已完成
2 期
enalidomide consolidation post allogeneic stem cell transplant for patients with high risk multiple myeloma failing to achieve stringent Complete ResponseMyelomaCancer - MyelomaACTRN12616000777493Alfred Health3
进行中（未招募）
不适用
Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002POEMS SYNDROMEMedDRA version: 9.1Level: SOCClassification code 10029205EUCTR2008-003202-33-ITISTITUTO CLINICO HUMANITAS
进行中（未招募）
不适用
Feasibility and efficacy of Lenalidomide maintenance after salvage immuno-chemotherapy induction in relapsed or refractory mantle cell lymphoma - a phase II study of the European MCL Networkpatients with relapsed or refractory mantle cell lymphoma after or not eligible for myeloablative treatmentMedDRA version: 12.0Level: PTClassification code 10026800Term: Mantle cell lymphoma recurrentMedDRA version: 12.0Level: PTClassification code 10026801Term: Mantle cell lymphoma refractoryEUCTR2008-000678-19-DEKlinikum der Universität München, Klinikum Großhadern60
进行中（未招募）
1 期
Pilot safety/tolerability study of Lenalidomide administered as monotherapy and in combination with standard chemotherapy for Acute Myeloid Leukaemia/high-risk myelodysplastic syndrome with structural abnormalities of chromosome 5 - AML Len5EUCTR2008-004891-28-GBeeds Teaching Hospitals Trust14